Filing Flows › Health Care › Prime Medicine (PRME)
Prime Medicine (PRME) earnings and revenue breakdown
Latest: Q4 2025 · 10-K filed Mar 3, 2026 · Prime Medicine (PRME) Q4 2025 earnings results →
Q4 2025 Revenue down 62% year over year to $838K
Prime Medicine made $838K in Q4 2025 (-62% Y/Y). Operating margin n/m, net loss $46.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $838K in Q4 2025, down 62% year over year and down 32% from the previous quarter.
Operating costs exceeded revenue by $48.6M, an operating margin of -5800.5%. Total costs grew 7% against a revenue fall of 62%. The fastest-growing cost line was General & admin (+20%). The quarter ended with a net loss of $46.1M, narrower than the previous quarter's $50.6M loss.
Operating cash flow was −$37.3M. Non-cash charges added back $1.9M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items added $2.4M. Capital expenditures of $290K exceeded it, leaving free cash flow of −$37.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 10-K | Mar 3, 2026 | $838K | -62% | n/m | −$46.1M | −$37.3M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $1.2M | +486% | n/m | −$50.6M | −$35.0M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $1.1M | — | n/m | −$52.6M | −$41.4M |
| Q1 2025 | 10-Q | May 8, 2025 | $1.5M | +146% | n/m | −$51.9M | −$48.9M |
| Q4 2024 | 10-K | Feb 28, 2025 | $2.2M | — | n/m | −$42.3M | $16.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Prime Medicine
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies.
In its own words, from its 10-K, filed Mar 3, 2026.
Prime Medicine against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -62% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PRME Prime Medicine | Q4 2025 | $838K | -62% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Prime Medicine 10-K on SEC EDGAR · CIK 1894562 · Biological Products, (No Diagnostic Substances)
13F: who owns PRME and who is buying
More on PRME
History
Every quarter: Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results